EICHOR
● Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Condition: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) · Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
About this study
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
This description comes directly from the study's public registry record.
Talk to the study team
Xiaojuan Lai · 15358160458 · lai_xiaojuan@vcarepharmatech.com
Always discuss trial participation with your own doctor first.
Locations (1)
| General Hospital of Northern Theater Command of Chinese PLA | Shenyang, Liaoning, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06577519